Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Recommendation of “Moderate Buy” by Analysts

Rapport Therapeutics, Inc. (NASDAQ:RAPP) has earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $50.80.

A number of equities research analysts recently commented on RAPP shares. BTIG Research reiterated a “buy” rating and issued a $47.00 target price on shares of Rapport Therapeutics in a research report on Monday. The Goldman Sachs Group restated a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. Finally, Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a report on Thursday, January 8th.

Rapport Therapeutics Stock Up 1.0%

Shares of Rapport Therapeutics stock opened at $30.54 on Tuesday. Rapport Therapeutics has a twelve month low of $7.73 and a twelve month high of $42.27. The business has a 50-day moving average price of $28.16 and a 200-day moving average price of $26.76. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -11.27 and a beta of 1.50.

Insider Buying and Selling at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 5,083 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $29.36, for a total value of $149,236.88. Following the sale, the chief executive officer directly owned 20,729 shares in the company, valued at $608,603.44. The trade was a 19.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David Bredt sold 8,500 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $29.02, for a total transaction of $246,670.00. Following the completion of the sale, the insider owned 387,075 shares in the company, valued at approximately $11,232,916.50. This trade represents a 2.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 69,669 shares of company stock worth $1,999,877 in the last ninety days. Company insiders own 13.57% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RAPP. Meeder Asset Management Inc. purchased a new position in Rapport Therapeutics in the fourth quarter worth about $37,000. Russell Investments Group Ltd. purchased a new stake in Rapport Therapeutics during the third quarter valued at approximately $43,000. Strs Ohio raised its position in Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after purchasing an additional 400 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Rapport Therapeutics by 64.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock valued at $70,000 after purchasing an additional 905 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock valued at $99,000 after purchasing an additional 4,582 shares during the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.